A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).
Andrew X. Zhu
Consultant or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Bayer; ImClone Systems; Novartis
Ian Chau
Consultant or Advisory Role - ImClone Systems
Jean-Frédéric Blanc
Honoraria - Bristol-Myers Squibb; ImClone Systems
Takuji Okusaka
Honoraria - Lilly
Research Funding - Lilly
Maria Rojas
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Ling Yang
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Ingo Von Broen
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly